Pancreatic cancer is an exceedingly malignant tumor in the digestive system, and its five-year survival rate is little more than 10%. Metabolic alterations are one of the hallmarks of tumor cells. Oncogenic Kras-activated pancreatic ductal adenocarcinoma (PDAC) cells depend heavily on an unconventional glutamine (Gln) catabolic pathway to sustain cell growth.
Click here for original story, Scientists identify O-GlcNAcylation as cause of pancreatic tumor growth by regulating MDH1
Source: Phys.org